Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

1) receptor blockade -- in one molecule to treat high blood pressure.

"We are very pleased with the results of this important Phase 2a trial and look forward to future studies which will further assess the potential of PS433540, perhaps even beyond blood pressure lowering," said Joseph A. Mollica, Ph.D., Chairman of the Board and Interim President and Chief Executive Officer of Pharmacopeia. "We believe PS433540's dual mechanism of action may have a positive effect on diabetic kidney disease."

Patients with diabetes are at an increased risk for many complications, including high blood pressure and diabetic kidney disease. Up to 73 percent of patients with diabetes have been or are being treated for high blood pressure,(5) and an estimated 20-30 percent of diabetic patients will progress to diabetic kidney disease,(6) a devastating disease that may require patients to undergo dialysis or a kidney transplant.(7)

Pharmacopeia recently initiated a 12-week, Phase 2b clinical trial with PS433540 to evaluate the compound's safety and efficacy at three different doses versus placebo in 375 subjects with Stage I and Stage II hypertension. The study will also compare blood pressure reductions for each dose with irbesartan. Pharmacopeia anticipates completion of the Phase 2b trial at the end of 2008.

About the Phase 2a study

In this prospective study, 234 men and women with Stage I and Stage II hypertension entered into a single blind placebo run-in period for 3-4 weeks, after which 114 were randomized to receive double blind study medication for four weeks. At the time of the database lock, 108 subjects were available for evaluation, 93 of whom had both baseline and follow-up ambulatory blood pressure measurements (placebo: 25; PS433540 200mg: 35; PS433540 500mg: 33). The primary endpoint was the subjects' change from baseline in mean 24-hour systolic ambulatory blood pressure after 4 weeks of treatment. Additionally, investigators evaluated
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Germany , and MARSEILLE, ... , Exclusive global license from University ... mutations, including next-generation sequencing (NGS) gene panels, for blood ... targeted by new test, indicate favorable prognosis for patients ... QIAGEN sees potential for developing companion diagnostics to ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New "Oxygen Sandwich" Device is First to Mimic Natural ... the major challenges to islet,cell transplantation as the treatment ... donor tissue supply. Patients often need a re-infusion of ... donor pancreas is,needed to provide the fragile islet cells ...
... Ozarelix Was Maintained For ... Up To Six Months, ... IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ) ... drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the 29th ...
Cached Medicine Technology:Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5
(Date:7/25/2014)... July 25, 2014 Ticket Down ... the board for the Guinness International Champions Cup match ... FC at Soldier Field on Sunday, July 27th. ... customer appreciation promo/coupon/offer code SOCCER-2014 for added savings. , ... for diehard soccer fans in North America. Countless international ...
(Date:7/25/2014)... The Gerontological Society of America (GSA) ... field of aging has chosen Heather M. ... California, Davis, as the 2014 recipient of the ... distinguished honor, presented by GSA,s Health Sciences Section, ... in recognition of outstanding and sustained contribution to ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
(Date:7/25/2014)... Houston, TX (PRWEB) July 25, 2014 ... Annual Family Fun Fest on Sunday, July 27 at ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, ... location in The Heights. , “We’re thrilled to ... this year,” said Heather Belcher who owns the Sugarland-Missouri ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2
... Effect Sept. 11; Online Resources and Helpline Now,Available, ... date of Pennsylvania,s Clean Indoor Air Act fast approaching, ... to help,them comply with the law that will ban ... portion of casino floors., Guidance and a downloadable ...
... MBF Healthcare,Acquisition Corp. (Amex: MBH ), ... today the amendment of the Stock Purchase,Agreement ... Solutions,Holdings, Inc. ("CHS"), based on the signed ... (the "Stock Purchase Agreement"). CHS is a,privately-owned, ...
... 2 Ethiopia,s Ministry of Health,recently signed a ... at helping the country reach the U.N.,s Millennium,Development ... do so., The agreement provides a framework ... Ethiopia and the partners who are,contributing to the ...
... even a year after routine was stopped, study says ... may help treat memory problems in adults, according to ... 138 people age 50 and older at increased risk ... led to modest improvements in cognitive function in adults ...
... benefit of nation,s 1st such law, passed in 2004 , , ... ill kids have made use of California,s pioneering paid family ... it exists, according to researchers at the Rand Corp. ... law. It is funded by employees through an automatic payroll ...
... Normal Weight Obesity: A Real Health Risk, ... are,highlights from the September issue of Mayo ... as often as you wish. Mayo Clinic ... for a fee.,Include the following subscription information ...
Cached Medicine News:Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Ethiopia First Nation to Sign National Health Partnership Compact 2Health News:Exercise May Help Prevent Age-Related Memory Loss 2Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 3Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: